Paratek Pharmaceuticals Operating Income

Paratek Pharmaceuticals (PRTK) currently reports a operating income of $-45M as of June 2023. That compares with $-68M in the prior-year period — up 34.4% year over year. Use the charts on this page to explore Paratek Pharmaceuticals's operating income history and peer comparisons.

Paratek Pharmaceuticals's operating income increased from $-68M to $-45M — a 34.4% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Paratek Pharmaceuticals reported $-45M in operating income as of June 2023. That compares with $-68M in the prior-year period — up 34.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-45M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Paratek Pharmaceuticals, and consider following PRTK for alerts when major investors trade the stock.

Paratek Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-45M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRTK with unrelated industries.